Vincenzo Di Marzo is one of the world's most prolific and influential cannabinoid scientists, with over 700 publications and more than 80,000 citations. Formerly at the Italian National Research Council in Naples, he relocated to Université Laval in 2018 to lead a Canada Excellence Research Chair program. Di Marzo's laboratory discovered the "endocannabinoidome" — the expanded family of endocannabinoid-like lipid mediators — and has been central to understanding how the endocannabinoid system regulates metabolism, appetite, gut function, and the microbiome. His work on the role of endocannabinoids in obesity and metabolic syndrome has opened new therapeutic avenues for cannabinoid-based medicines targeting metabolic disease.
Key Contributions
1Coined and defined the "endocannabinoidome" — the expanded family of endocannabinoid-related lipid mediators
2Elucidated the biosynthesis and degradation pathways of anandamide and 2-AG
3Demonstrated that the endocannabinoid system regulates energy balance and appetite ("the endocannabinoid system and the control of food intake")
4Established the gut microbiome as a regulator of endocannabinoid tone
5Discovered that obesity is associated with overactivation of the peripheral endocannabinoid system
6Identified FAAH and MAGL as therapeutic targets for endocannabinoid-based medicines
Selected Publications
The Endocannabinoid System and Its Therapeutic Exploitation
5,600 citations
Nature Reviews Drug Discovery · 2004
Comprehensive review of the endocannabinoid system as a therapeutic target, covering CB1/CB2 receptors, endocannabinoid biosynthesis/degradation, and therapeutic applications in pain, neurodegeneration, cancer, and metabolic disease. One of the most-cited reviews in cannabinoid pharmacology.
Gut Microbiota Controls Adipose Tissue Expansion, Gut Barrier and Glucose Metabolism: Novel Insights into Molecular Targets and Interventions Using Prebiotics
890 citations
British Journal of Pharmacology · 2015
Demonstrated that gut microbiota modulates endocannabinoid tone in adipose tissue and gut epithelium, linking microbiome composition to metabolic syndrome via endocannabinoid signaling. Established the gut microbiome-endocannabinoidome axis.
Endocannabinoids: Endogenous Cannabinoid Receptor Ligands with Neuromodulatory Action
2,400 citations
Trends in Neurosciences · 1998
Landmark review establishing the endocannabinoid system as a retrograde neuromodulatory system, with anandamide and 2-AG acting as "on-demand" lipid messengers that suppress presynaptic neurotransmitter release. Defined the canonical mechanism of endocannabinoid signaling.